Shots:
- The EMA has received an application for a higher dose of Wegovy (semaglutide 7.2mg, SC) to treat obesity
- Application was backed by the 72wk. STEP UP trial assessing Wegovy (7.2mg) vs Wegovy (2.4mg) & PBO alongside lifestyle intervention in 1,407 adults without diabetes (BMI ≥30kg/m²), & the 72wk. STEP UP T2D trial assessing Wegovy (7.2mg) vs PBO in 512 adults with obesity & T2D
- The STEP UP trial showed an average weight loss of 21% in people with obesity, with a third of subjects losing ≥25% of their body weight compared to PBO
Ref: Novo Nordisk | Image: Novo Nordisk| Press Release
Related News:- Novo Nordisk Enters a ~$2.2B Deal with Septerna to Develop Oral Small Molecules for Cardiometabolic Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
